Y-mAbs Therapeutics, Inc. (YMAB) Social Stream
Y-MABS THERAPEUTICS INC (YMAB) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering YMAB.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 6 | $68 | $39 | $54.4 | $6.82 | 697.65% |
| 2021-11-16 | 6 | $68 | $30 | $49 | $6.82 | 618.48% |
| 2021-12-22 | 6 | $68 | $25 | $46.2 | $6.82 | 577.42% |
| 2022-01-03 | 6 | $68 | $25 | $45.6 | $6.82 | 568.62% |
| 2022-01-06 | 6 | $68 | $25 | $43.4 | $6.82 | 536.36% |
| 2022-02-17 | 6 | $68 | $15 | $41.4 | $6.82 | 507.04% |
| 2022-02-25 | 6 | $68 | $15 | $40 | $6.82 | 486.51% |
| 2022-02-28 | 6 | $63 | $15 | $35.8 | $6.82 | 424.93% |
| 2022-04-21 | 6 | $63 | $15 | $33.8 | $6.82 | 395.6% |
| 2022-05-10 | 6 | $63 | $15 | $30.8 | $6.82 | 351.61% |
| 2022-06-07 | 6 | $63 | $15 | $29 | $6.82 | 325.22% |
| 2022-08-13 | 8 | $63 | $15 | $29.571 | $6.82 | 333.59% |
| 2022-08-15 | 8 | $63 | $15 | $29.285 | $6.82 | 329.4% |
| 2022-10-26 | 8 | $63 | $16 | $29.571 | $6.82 | 333.59% |
| 2022-10-28 | 8 | $63 | $16 | $28.857 | $6.82 | 323.12% |
| 2022-10-31 | 8 | $27 | $6 | $16.875 | $6.82 | 147.43% |
| 2022-11-09 | 8 | $27 | $6 | $15 | $6.82 | 119.94% |
| 2022-12-02 | 8 | $27 | $4 | $13.285 | $6.82 | 94.79% |
| 2022-12-15 | 8 | $27 | $4 | $13.142 | $6.82 | 92.7% |
| 2023-01-05 | 8 | $20 | $5 | $12.285 | $6.82 | 80.13% |
| 2023-01-26 | 8 | $20 | $5 | $12.285 | $6.82 | 80.13% |
| 2023-01-27 | 8 | $20 | $4 | $12 | $6.82 | 75.95% |
| 2023-02-08 | 8 | $20 | $4 | $12.142 | $6.82 | 78.04% |
| 2023-03-31 | 7 | $20 | $4 | $12.142 | $6.82 | 78.04% |
| 2023-04-04 | 7 | $18 | $4 | $10.714 | $6.82 | 57.1% |
| 2023-05-09 | 7 | $21 | $4 | $11.142 | $6.82 | 63.37% |
| 2023-05-10 | 7 | $21 | $6 | $12.714 | $6.82 | 86.42% |
| 2023-05-15 | 7 | $21 | $7 | $13.571 | $6.82 | 98.99% |
| 2023-06-06 | 8 | $21 | $7 | $12.875 | $6.82 | 88.78% |
| 2023-07-25 | 8 | $22 | $7 | $13 | $6.82 | 90.62% |
| 2023-08-14 | 8 | $22 | $5 | $11.857 | $6.82 | 73.86% |
| 2023-09-20 | 8 | $22 | $5 | $11.714 | $6.82 | 71.76% |
| 2023-11-15 | 7 | $22 | $5 | $12.5 | $6.82 | 83.28% |
The Trend in the Analyst Price Target
Over the past 21 months, YMAB's average price target has gone down $28.9.
Over the past 45 weeks, YMAB's average upside potential has been 112.83%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-08 | 7 | 20 | 4 | 12.142 | 4.280 | 183.69% |
| 2023-04-04 | 7 | 18 | 4 | 10.714 | 5.750 | 86.33% |
| 2023-05-09 | 7 | 21 | 5 | 11.571 | 9.230 | 25.36% |
| 2023-10-17 | 7 | 22 | 5 | 12.833 | 5.395 | 137.87% |
| 2023-10-17 | 7 | 22 | 5 | 12.500 | 5.395 | 131.7% |
YMAB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.96 | 4 | 0 | 2 | 0 | 0 | 7 |
The Trend in the Broker Recommendations
YMAB's average broker recommendation rating worsened by 0.5 over the prior 15 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, Y-MABS THERAPEUTICS INC's variance in analysts' estimates is lower than -3621.91% of them.
- Y-MABS THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 3390.4% of all US stocks.
- YMAB has a greater average analyst price target than 1225.15% of stocks in the mid market cap category.
- In terms of how Y-MABS THERAPEUTICS INC fares relative to stocks in the mid market cap category, note that its number of analysts covering the stock is greater than 1772.69% of that group.
Stocks similar to Y-MABS THERAPEUTICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are DCPH, AUPH, and ANAB.
View All Top Stocks by Price Target
Is YMAB a Buy, Hold or Sell? See the POWR Ratings now!